Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 159234

Sabadell, Barcelona 08208

0 studies enrolling now · 1 studies all time

What they study most

Crohn's Disease

Studies at this site

• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment — Completed